24 January 2022
Grade 7: £ 33,309 - £ 40,927 with a discretionary range to £ 44,706 per annum. Apply by 16 February 2022
18 January 2022
A novel immunotherapeutic called VTP-600, based on Ludwig Oxford’s Benoit Van den Eynde’s preclinical research, is being tested in patients for the first time.
5 January 2022
Grade 7: £33,309 - £40,927 with a discretionary range to £44,706 per annum. Apply by 7 February 2022.
25 November 2021
A study from Professor Colin Goding’s group finds an unexpected mechanism controlling growth vs senescence in cancer.
11 November 2021
Interactions between transcription factors and the chromatin environment provide barriers controlling cell differentiation, according to research by Professor Yang Shi and colleagues.
19 October 2021
Dr Tammie Bishop’s and Professor Sir Peter Ratcliffe’s groups shed light on the developmental origins of inherited cancers with mutations in the HIF pathway.
1 October 2021
Our new Leadership Fellow launches a research group in cancer epigenetics and epitranscriptomics.
30 September 2021
Dr Benjamin Schuster-Böckler will join the Turing network for 2021-2022 to further his research in cancer big data.
21 September 2021
Ludwig Oxford welcomes Ellie Barnes to our community, which she has joined as a Ludwig Adjunct Scholar.
3 September 2021
A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.
9 August 2021
Claudia Zagami from the Boccellato lab was selected to give a talk on 3D tissue models for studying disease.
30 June 2021
Professor Stefan Constantinescu joins Ludwig Oxford to expand his research programme in cancer epigenetics.